Background
Streptococcus pneumoniae can cause pneumonia and invasive pneumococcal diseases (IPDs), which result in considerable morbidity and mortality worldwide [
1,
2]. The Advisory Committee on Immunization Practices recommends the use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) or the 13-valent pneumococcal conjugate vaccine (PCV13) for all the elderly (age ≥ 65 years) and for immunocompromised adults [
3]. In Japan, the PPSV23 coverage of people aged ≥ 65 years was 32.4% in 2019 [
4], and that of the PCV13, which is not covered by Japanese universal health insurance, has not been reported because of the extremely small number of people vaccinated. The effectiveness of the PPSV23 in preventing IPD has been reported, its effectiveness in preventing pneumococcal pneumoniae has been inconsistent [
5‐
7]. Some researchers have targeted both healthy individuals and patients with various diseases at nursing home residences [
6,
8].
We hypothesized that the PPSV23 would be useful in preventing pneumococcal pneumonia in elderly outpatients with chronic respiratory diseases. This study aimed to assess the effectiveness of the PPSV23 among elderly outpatients in clinical practice.
Methods
Study design and population
This study was a retrospective case–control design. The target population was defined as outpatients aged ≥ 65 years, with chronic respiratory diseases, treated between 2015 and 2017 in the respiratory department of Shizuoka General Hospital. From this sample, the case and control groups consisted of patients with and without pneumococcal pneumonia, respectively. Patients who had been vaccinated with PCV13 were excluded.
Diagnosis of pneumococcal pneumonia
Respiratory physicians diagnosed pneumonia based on clinical findings such as fever, hypothermia, chills, cough, sputum production, pleuritic chest pain, fatigue, tachypnea, white blood cell count > 9300, or < 4000 cells/mm
3, and new pulmonary infiltrates on chest radiography [
2]. In this study, all patients with pneumonia met these criteria. Pneumococcal pneumonia was diagnosed based on the positive results of urine pneumococcal antigen and sputum culture, but a negative blood culture for pneumococcus.
Definitions
The chronic respiratory diseases in this study included lung cancer, asthma, chronic obstructive pulmonary disease (COPD), interstitial pneumonia, pulmonary non-tuberculous mycobacteriosis (NTM), pulmonary tuberculosis, and others. The history of PPSV23 vaccination was obtained from medical records and declarations by patients or their families. Patients were considered vaccinated when they had received the PPSV23 within five years prior to the diagnosis of pneumonia. Patients without medical records or whose families had no knowledge of their vaccination statuses were considered unvaccinated.
Statistical analysis
The chi-squared tests for categorical variables and t-tests for continuous variables were used in comparing both groups. To evaluate the effectiveness of the PPSV23, we performed a logistic regression analysis, and then the odds ratio (OR), 95% confidence interval (CI), and
p value (based on Wald test) were calculated. The adjusted OR was estimated by the quantile stratification method of propensity scores. The propensity score was estimated using multivariate logistic regression models with potential confounders as covariates, which included all variables of Table
1. We also made two subsets: those ≥ 70 years, and ≥ 75 years, and compared their adjusted ORs with that in all patients. As a sensitivity analysis, we estimated double-robust adjusted OR in case–control studies under causal inference [
9], and we confirmed whether the point estimation of OR, as mentioned above, was overestimating the effect.
Table 1
Characteristics of patients with and without pneumococcal pneumonia
Age, yearsa | 76.2 ± 7.3 | 75.1 ± 6.7 | 0.127 |
65–69 | 32 (19.5) | 984 (24.3) | 0.153 |
70–74 | 44 (26.8) | 1,098 (27.1) |
75–79 | 36 (22.0) | 950 (23.4) |
80 + | 56 (34.1) | 1,063 (26.2) |
Male (vs. female) | 113 (68.9) | 2,525 (62.3) | 0.100 |
Smoking | | | 0.001 |
Non-smokers | 37 (22.6) | 1,198 (29.6) |
Current smokers | 108 (65.9) | 2,068 (51.0) |
Ex-smokers | 19 (11.6) | 788 (19.4) |
Chronic respiratory diseases (vs. absent) | | | |
Asthma | 30 (18.3) | 685 (16.9) | 0.671 |
COPD | 42 (25.6) | 959 (23.6) | 0.574 |
Lung cancer | 45 (27.4) | 1,594 (39.3) | 0.002 |
Interstitial pneumonia | 29 (17.7) | 703 (17.3) | 0.916 |
NTM | 10 (6.1) | 449 (11.1) | 0.054 |
Othersb | 48 (29.3) | 746 (18.4) | 0.001 |
Diabetes (vs. absent) | 65 (39.6) | 1,209 (29.8) | 0.023 |
Chronic heart disease (vs. absent) | 95 (57.9) | 1,891 (46.6) | 0.005 |
Chronic kidney disease (vs. absent) | 13 (7.9) | 299 (7.4) | 0.761 |
Systemic corticosteroid user (vs. absent) | 65 (39.6) | 1,189 (29.3) | 0.007 |
To confirm the efficacy of the vaccine for each age group (65 to < 70 years, 70 to < 75 years, and ≥ 75 years), crude ORs, ORs adjusted for risk factors, and their 95% confidence intervals were calculated. Risk factors for pneumococcal pneumonia were identified as follows. Variables for which the p value of the comparison test between the case and control groups was less than 0.05 were considered as candidate risk factors, and these variables were entered into a multivariate logistic regression model. In this multivariate model, variables with p values less than 0.05 were identified as risk factors. Furthermore, to extract variables containing different categories of pneumococcal pneumonia proportions in different age groups, an interaction term test using a logistic regression model was performed.
A p value of < 0.05 was considered to be statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Discussion
This study found that the PPSV23 prevented pneumococcal pneumonia in older patients (age ≥ 65 years) with chronic respiratory diseases, and could be more effective for the elderly (patients aged ≥ 70 years). To the best of our knowledge, this is the first real-world study that assesses the effectiveness of the PPSV23 in older patients with chronic respiratory disease in a single center.
In previous studies, the effectiveness of the vaccine against pneumococcal pneumonia was controversial. In the results of a meta-analysis of 18 randomized trials [
5], the PPSV23 reduced the risk of IPDs such as bacteremia, meningitis, and bacteremic pneumonia (OR [95% CI]: 0.26 [0.15–0.46]) and pneumococcal pneumonia (0.46 [0.25–0.84]). However, some studies reported that the PPSV23 did not reduce pneumococcal pneumonia [
6,
7,
10]. The EVAN-65 study in community-dwelling patients [
11] showed that the hazard ratios (HR) for the risk of pneumococcal pneumonia in vaccinated patients compared with non-vaccinated patients were not different (HR [95% CI]: 0.61 [0.35–1.06]). Similarly, another study in elderly patients with chronic respiratory diseases showed no difference (0.76 [0.30–1.90]) [
12]. These conflicting results can be due to the difficulties of accurately diagnosing pneumococcal pneumonia and the use of non-validated diagnostic tests [
13]. In this study, we included non-invasive cases according to specific diagnostic criteria of pneumonia, urine pneumococcal antigen, and sputum culture, and we are convinced that these results are close to correct.
One previous case–control study suggested that 85–90% of adults aged 55 and younger achieved the prevention of invasive pneumococcal infections, but this effect was reduced with increasing age, and no protection was shown in the population aged ≥ 80 years [
14]. Another study suggested that the prevention of community-onset pneumococcal pneumonia was effective in people aged 65-75 years but not effective in those aged ≥ 75 years in Japan [
15]. The population-based retrospective cohort study in Germany reported that the prevention of pneumococcal pneumonia was not effective at all in people aged ≥ 80 years [
16]. These studies suggest that poorer effectiveness might be due to immunosenescence, which refers to the decline of the immune system associated with aging [
17]. However, this study found that the OR was much decreased in older people, which could imply that older people can acquire antibodies with the PPSV23 vaccination, and we proposed that older people be re-vaccinated because of an anticipated decline in the effectiveness of the vaccine over time.
Almost all patients with chronic respiratory diseases in this study had risk factors for pneumonia [
18]. Previously, most studies on the PPSV23 targeted nursing home residences or healthy adults, and controversial results have been reported on non-invasive pneumonia [
8]. Our findings suggest the importance of vaccinating chronic respiratory patients in clinical practice.
There were several limitations. First, this study was a retrospective single-center study, and a complete confounding adjustment was not done. Second, we did not assess the severity of the underlying diseases. The study population was biased, consisting mainly of moderate to severe disease cases. Third, we did not regularly identify the serotype of each pneumococcal pneumonia. Fourth, the vaccination status of unvaccinated persons was defined based on the lack of medical records of vaccination, and some vaccinated patients may have been misclassified as unvaccinated. Fifth, in this study, we were not able to investigate the patients' history of seasonal influenza vaccination. This may affect the risk of pneumococcal infections.
In summary, the PPSV23 can be useful in preventing pneumococcal pneumonia among the elderly with chronic respiratory diseases.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.